JGC
ACER

J. Goldman & Co’s Acer Therapeutics Inc ACER Stock Holding History

J. Goldman & Co’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-360,000
Closed -$943K – 554
2020
Q4 		$943K Buy
+360,000
New +$969K 0.05% 241
2020
Q1 		– Sell
-73,510
Closed -$295K – 367
2019
Q4 		$295K Sell
73,510
-79,290
-52% -$269K 0.02% 231
2019
Q3 		$487K Buy
152,800
+52,799
+53% +$155K 0.04% 228
2019
Q2 		$390K Buy
+100,001
New +$1.91M 0.03% 233
2018
Q3 		– Sell
-40,684
Closed -$879K – 422
2018
Q2 		$879K Sell
40,684
-49,518
-55% -$940K 0.05% 263
2018
Q1 		$1.74M Sell
90,202
-17,798
-16% -$326K 0.07% 225
2017
Q4 		$1.5M Buy
+108,000
New +$1.76M 0.08% 210

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

J. Goldman & Co's ACER Position: Q1 2021 in Review

J. Goldman & Co sold out of Acer Therapeutics Inc (ACER) in Q1 2021, closing a stake of 360,000 shares — an estimated $943K sold.

J. Goldman & Co first reported a position in ACER in Q4 2017 and held it in 7 quarters. The position peaked at $1.74M in Q1 2018. 30 funds tracked by Wall St. Rank hold ACER as of Q1 2021.

  • J. Goldman & Co reported no remaining Acer Therapeutics Inc position as of Q1 2021 after selling out during the quarter.
  • J. Goldman & Co sold 360,000 Acer Therapeutics Inc shares in Q1 2021, an estimated $943K.
  • J. Goldman & Co first reported a position in Acer Therapeutics Inc in Q4 2017 and held it in 7 quarters.
  • J. Goldman & Co's Acer Therapeutics Inc position peaked at $1.74M in Q1 2018.
  • 30 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2021.

Based on J. Goldman & Co's 13F filing for Q1 2021, filed 17 May 2021.